PUBLISHER: DataM Intelligence | PRODUCT CODE: 1136901
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1136901
The Chronic Kidney Disease Drugs Market was valued at US$ 10,923.29 million in 2021 and is estimated to reach US$ 19,427.41 million by 2029, growing at a CAGR of 6.58% during the forecast period (2022-2029).
Chronic kidney disease, also known as chronic kidney failure, describes the gradual loss of kidney function. Kidneys filter the wastes and excess fluids from blood, which are then excreted in the urine.
The major driving forces are the increasing prevalence of chronic kidney disease, the continuous requirement for drugs to treat the patients along with easy availability, the increase in research and development, technological advancements and the rising geriatric population are expected to drive market growth.
The rising requirement for chronic kidney disease drugs is expected to drive market growth.
The global market for chronic kidney disease drugs is primarily driven by the rising demand for drugs related to chronic kidney disease. According to the Centre for Disease Control and Prevention report 2021, the increase in chronic kidney disease causes more deaths. It is an under-recognized public health crisis. It affects approximately 37 million people in the U.S., equivalent to 15% of the adult population or more than one in seven adults. The high prevalence of obesity, hypertension and diabetes are some of the reasons that are causing chronic kidney disease. Hence, increasing demand for drugs for the treatment of chronic kidney disease.
Increasing technological advancements by the major key players are driving the market's growth. Various novel research studies and innovations are taking place in the market. For instance, in Apr 2021, AstraZeneca announced the approval of Farxiga (dapagliflozin) by the U.S. Food and Drug Administration. Farxiga is an inhibitor of sodium-glucose cotransporter 2 used to minimize the risk associated with estimated glomerular filtration rate, cardiovascular death, end-stage kidney disease, and chronic kidney disease patients.
Chronic kidney disease drugs' high cost and side effects will hamper the market's growth.
The risks associated with chronic kidney disease drugs such as medication-related complications as a variety of medications are prescribed to minimize the chronic kidney disease growth that leads to some complications such as renal functions degradation of the patient, the high cost, the stringent regulatory approval process, delayed diagnosis of chronic kidney disease due to vague symptoms, the inclination to generic medication options, and the patent expiry of drugs.
The calcium channel blockers segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The calcium channel blockers segment is the highest market holder in the global chronic kidney disease drugs market. The increased number of chronic kidney diseases leads to the growing demand for treatment drugs and research activities. Calcium channel blockers prevent, treat or improve symptoms in various conditions, such as high blood pressure and coronary artery disease, which can increase the risk of chronic kidney diseases. Presently, dominant calcium channel blockers utilized across the world are phenyl alkyl amines (verapamil), benzothiazepines (diltiazem), and dihydropyridines (nifedipine and amlodipine). A report published in Aug 2022 titled "Renal Function in Hypertensive Patients Receiving Cilnidipine and L-Type Calcium Channel Blockers" reported that around 65-95% of patients with chronic kidney disease are suffering from hypertension. The first line of treatment drugs for hypertension are Calcium channel blockers. These calcium channel blockers act as antihypertensive medicines used widely due to their high tolerability, efficacy in lowering the level of blood pressure, and hypertension-related cardiovascular or renal consequences. For instance, in Aug 2022, AstraZeneca from DELIVER phase III trial released detailed results showing Farxiga reducing cardiovascular death or heart failure.
North America holds the largest market share of the global chronic kidney disease drugs market.
North America dominates the global chronic kidney disease drug market, primarily attributed to the growing prevalence of chronic kidney diseases, kidney failure, and diabetes. The rapid adoption of drugs for CKD is likely to enhance the growth of chronic kidney disease drugs. Furthermore, factors such as the high spending of GDP on healthcare, growing government initiatives, and reimbursement policies in advanced medical treatment options are likely to enhance the growth of the region's chronic kidney disease drugs market.
Moreover, extensive research activities are undertaken by the most prominent players in the area, and the rising demand for technologically advanced treatment will propel the market. Also, key players manufacturing chronic kidney disease treatment drugs are boosting the market. For instance, in Jul 2021, Bayer announced the approval of Kerendia (Finerenone), first non-steroidal, mineralocorticoid receptor antagonist, by the U.S. FDA. Finerenone is used to minimize the risk of decline in estimated glomerular filtration rate, cardiovascular death, end-stage kidney disease and chronic kidney disease patients with type 2 diabetes.
The chronic kidney disease drug market is moderately competitive with local and global companies. Key players contributing to the market's growth are Sanofi S.A., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc., Kissei Pharmaceutical Co, AbbVie Inc., GlaxoSmithKline Plc, Amgen Inc., Akebia Therapeutics and more.
The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the cardiac ablation devices market. For instance, in Aug 2022, CSL Limited announced the completion of the acquisition of Vifor Pharma AG. CSL got all the necessary regulatory clearances required for Vifor's acquisition.
Pfizer Inc. is a multinational pharmaceutical company that also works in the biotechnology domain. It was established in 1849 and is headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, and immunology.
RETACRIT: Retacrit is a kind of erythropoietin man-made protein made in a laboratory. It is an erythropoiesis-stimulating agent used to treat the anemia caused due to chronic kidney disease.
The global chronic kidney disease drugs market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.
LIST NOT EXHAUSTIVE